Harnessing bioinformatics to find new drug combinations for breast cancer
The bimonthly magazine Clinical OMICs interviews Patrick Aloy, ICREA researcher and leader of the Structural Bioinformatics and Network Biology lab at IRB Barcelona, about his study published in the journal Cancer Research. Patrick Aloy talks about his work as a leader of team that uses bioinformatics approaches to uncover new drug combinations for the treatment of breast cancer.
The seventh video in the series Meet Our Scientists, "Networks of Life", presents the work performed by Patrick Aloy. Watch the video (Subtitles available in Spanish, Catalan and English).
Related content
News
Researchers at IRB Barcelona discover a new mechanism in estrogen receptor-positive breast cancer cells.
The inhibition of CPEB2, a key factor in the estrogen signalling pathway, causes cancer cells to proliferate less and protects mice against luminal breast cancer.
The European Commission has awarded funding to 17 research projects in a special call announced to tackle the coronavirus. IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy, is participating in one of these projects, together with other research centres. The project, called RiPCoN, will perform a computational study of the interactions between coronavirus and human cells, with the aim to identify drugs (already on the market or in trials) that can halt the spread of the virus.
The newspaper ABC has reported on a new project to be launched by IRB Barcelona researcher Roger Gomis thanks to a grant from the Fundación Fero y Mango. Focusing on luminal breast cancer, one of the most common subtypes, the project aims to decipher the “dialogue” between tumour cells and bone stem cells. This information can then be used to design therapeutic targets and to limit the capacity of these cells to metastasize. “This is a groundbreaking approach to tackle metastasis in this kind of cancer,” says Gomis.
